CN118591554A - 抗人cxcl1抗体 - Google Patents

抗人cxcl1抗体 Download PDF

Info

Publication number
CN118591554A
CN118591554A CN202380018348.0A CN202380018348A CN118591554A CN 118591554 A CN118591554 A CN 118591554A CN 202380018348 A CN202380018348 A CN 202380018348A CN 118591554 A CN118591554 A CN 118591554A
Authority
CN
China
Prior art keywords
amino acid
seq
human
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380018348.0A
Other languages
English (en)
Chinese (zh)
Inventor
八代正和
山本百合惠
吉冈亚希子
中村康司
柳内浩之
井上俊和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public University Legal Person Osaka
Chiome Bioscience Inc
Original Assignee
Public University Legal Person Osaka
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Public University Legal Person Osaka, Chiome Bioscience Inc filed Critical Public University Legal Person Osaka
Publication of CN118591554A publication Critical patent/CN118591554A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202380018348.0A 2022-01-27 2023-01-26 抗人cxcl1抗体 Pending CN118591554A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-011107 2022-01-27
JP2022011107 2022-01-27
PCT/JP2023/002533 WO2023145844A1 (ja) 2022-01-27 2023-01-26 抗ヒトｃｘｃｌ１抗体

Publications (1)

Publication Number Publication Date
CN118591554A true CN118591554A (zh) 2024-09-03

Family

ID=87471580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380018348.0A Pending CN118591554A (zh) 2022-01-27 2023-01-26 抗人cxcl1抗体

Country Status (10)

Country Link
US (1) US20250154240A1 (https=)
EP (1) EP4471057A4 (https=)
JP (1) JPWO2023145844A1 (https=)
KR (1) KR20240137027A (https=)
CN (1) CN118591554A (https=)
AU (1) AU2023213334A1 (https=)
CA (1) CA3249959A1 (https=)
IL (1) IL314512A (https=)
TW (1) TW202342528A (https=)
WO (1) WO2023145844A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060413A1 (en) * 2024-09-16 2026-03-19 Calgent Biotechnology Co., Ltd. Single chain antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP2997042B1 (en) * 2013-05-17 2019-08-07 Centre National de la Recherche Scientifique (CNRS) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
US20170058029A1 (en) 2014-05-02 2017-03-02 Chiome Bioscience Inc. Human antibody-producing cell
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
US11292832B2 (en) * 2019-01-28 2022-04-05 Charles J. Rosser Compositions and methods for treatment of diseases involving CXCL1 function
JP7471156B2 (ja) 2020-06-29 2024-04-19 ギガフォトン株式会社 極端紫外光集光ミラー及び電子デバイスの製造方法

Also Published As

Publication number Publication date
AU2023213334A1 (en) 2024-09-05
IL314512A (en) 2024-09-01
EP4471057A1 (en) 2024-12-04
WO2023145844A1 (ja) 2023-08-03
JPWO2023145844A1 (https=) 2023-08-03
EP4471057A4 (en) 2026-03-04
KR20240137027A (ko) 2024-09-19
US20250154240A1 (en) 2025-05-15
TW202342528A (zh) 2023-11-01
CA3249959A1 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
CN114514246B (zh) 对nectin-4具有特异性的抗体及其用途
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
US11498972B2 (en) Anti-OX40 antibody and use thereof
JP7842703B2 (ja) 抗Ｃｌａｕｄｉｎ１８．２抗体およびその使用
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
RU2571224C2 (ru) Гуманизированные антитела против axl
CA2798778C (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
US20190330350A1 (en) Anti-pd-l1 monoclonal antibodies and fragments thereof
KR102349370B1 (ko) 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
US11912777B2 (en) Antibodies binding TNFR2 and uses thereof
US20240043568A1 (en) Development of new tumor engager therapeutic drug and use thereof
KR20180054492A (ko) CD66c에 특이적으로 결합하는 항체 및 그의 용도
CN116059341A (zh) 药物组合物及用途
KR102373502B1 (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
EP2270053A1 (en) Humanized AXL antibodies
CN118591554A (zh) 抗人cxcl1抗体
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
US12331133B2 (en) Therapeutic antibodies for treating lung cancer
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
CN121008043A (zh) Axl-gas6复合物的检测方法及在心肌梗死患者中的应用
HK40006061B (en) Prl3 antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination